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Abstract 
 
Background: In patients with ulcerative colitis (UC), the repeated cycle of injury and repair of intestinal mucosa 
has been reported to increase the risk of colon cancer. So, a safe and efficient therapy is required for the 
treatment and prophylaxis for the disease.This study aims to investigate the efficacy of Calendula officinalis 
extract in treatment of experimentally induced ulcerative colitis in dog animal model.  
 
Methods: During fall 2010, 10 out-bred female German dogs (1-2 years old; weighs of 20-25 kg) were enrolled. 
Ulcerative colitis was induced with 6% acetic acid as enema and method of treatment was retrograde (via ene-
ma) too by C. officinalis.  
 
Results: Loose stools, diarrhea, gross bleeding and loss of body weight happened after administration of acetic 
acid and crypt damage, loss of epithelium, infiltration of inflammatory cells and depletion of goblet cells were 
noticed histologically. C. officinalis could successfully resolve the damages of UC.  
 
Conclusion: Treatment with C. officinalis can broaden the current therapy options for UC. 
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Introduction 
 
Inflammatory bowel diseases (IBD) are chronic fluctu-
ating inflammatory diseases with unknown clear caus-
es; believed to be multifactorial and challenging in 
management of the disease. IBD has divided into two 
major group including Ulcerative colitis (UC) that in-
volves the mucosa of the rectum and colon and Crohn's 
disease (CD). Patients with UC complain from bloody 
diarrhea, abdominal pain, weight loss, chronic pain, 
side effect of drug management and especially in long 
term, colon cancer related signs. UC is idiopathic, 
chronic, relapsing and its inflammatory condition is 
immunologically mediated in the lining of the rectum 
and colon. In adults, UC is most commonly diagnosed 
between the third and fourth decades of life, with no 
difference between males and females.
1 
A decrease in antioxidant defense against increasing 
oxidative materials have been revealed in colonic muco-
sal biopsies of patients with UC.
2 The therapeutic strate-
gy for UC has focused on anti-inflammatory agents.
3 
Glucocoticoids and salicylates as well as biological 
agents against tumor necrosis factor-α (TNF-α) were 
used in treatments of UC.
4 Corticosteroids as another 
therapeutic measure are potent inhibitors of T-cell acti-
vation and pro-inflammatory cytokines,
5 while fewer 
side effects were shown for steroids used via enema 
compared to a systemic use.
6  
Calendula officinalis L. known as calendula is a 
flower from the Asteraceae family has several medi-
cal properties including bactericidal, antiseptic, anti-
inflammatory and analgesic entities.
7 The petals and 
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pollen contain triterpenoid esters (an anti-inflammatory 
property) and the carotenoids flavoxanthin and auroxan-
thin (an antioxidant property and the source of its yel-
low-orange coloration).
8 The leaves and stems contain 
other carotenoids, mostly lutein (80%) and zeaxanthin 
(5%), and beta-carotene and its extract contains sapo-
nins, resins and essential  oils
7,9 that enhance the level of 
endogenous anti-oxidant catalases,  elismutases and glu-
tathione having anti-oxidant effects.
10 C. officinalis has 
been successfully used for preventing UV-induced oxi-
dative stresses,
11 melanoma metastasis control,
12 im-
provement of wound healing processes
13 and angiogen-
esis activation.
14 
Several studies have used herbal extracts for treat-
ment of IBD.
14,15 In this regards, Medhi et al. demon-
strated that Manuka honey has synergic effects with 
sulfasalazine in enhancing antioxidant defense system 
in experimentally induced UC model in rats.
14 Souza et 
al. showed that enemas of budesonide and probiotics 
enhance the mucosal trophism in experimental colitis 
in rats.
16 According to anti-inflammatory entities of C. 
officinalis  and lack of data regarding its efficacy in 
treatment of UC, this study was performed to investi-
gate the efficacy of C. officinalis extract in treatment of 
experimentally induced UC in a dog model. 
 
 
Materials and Methods 
 
In this experimental study being performed during 
fall 2010 in Laboratory Animal Center of Shiraz Uni-
versity of Medical Sciences, 10 out-bred female 
German dogs (1-2 years old; weighs of 20-25 kg) 
were enrolled. All dogs were housed individually and 
fed standard food throughout the experiment. The 
dogs were initially evaluated for any illness by physi-
cal examination and laboratory screening. All exper-
iments were carried out under aseptic conditions and 
the protocol of anesthesia; surgical procedures, post-
operative care and sacrifice were identical for all ani-
mals. The study was approved by the Ethics Commit-
tee of Shiraz University of Medical Sciences (registra-
tion number: 90-5077). Study animals were handled in 
conformity with guidelines for the care and handling of 
laboratory animals provided by Shiraz Laboratory An-
imals Center. The dogs were randomly allocated to two 
study groups (5 in each group) to receive C. officinalis 
extract or saline enema as treatment. A 40% C. offici-
nalis solusion was prepared by Pharmacology Depart-
ment of Shiraz University of Medical Sciences.  
Ulcerative colitis was induced in all the dogs. For 
this purpose animals were kept NPO for two days and 
bowel preparation was performed for all of them on the 
day of induction. Bowel preparation was done using 30 
ml of Senagraph syrup (Sina Daru, Tehran, Iran) 
through a nasogastric tube. To check for presence of 
ulcers in the colon, 0.1 mg/kg of acepromazine was ad-
ministered. Only water was given ad libitum to animals 
during these two days. Ulcerative colitis was induced by 
acetic acid 6% (6 mg/kg/stat) enema through rectal tube. 
After 7 days of enema, the colon was evaluated by 
a rigid rectosigmoidoscope to evaluate any presence 
of any gross mucosal ulcer as described by Morris et 
al. (1994)
17 (Table 1). Multiple biopsies were provid-
ed from mucosa in 10, 20 and 30 cm proximal to the 
anal verge and transferred into the formalin for histo-
logical studies (H&E staining) as described by 
Mehrabani  et al. (2009)
18 (Table 2). In histological 
study, the samples were examined at x10 and x20 
magnification for presence or absence of ulcer, muco-
sal cell depletion, inflammatory cysts, congestion, 
mucosal atrophy, submucosal edema, inflammatory 
cells, vascular dilatation, etc. At magnification of 
x40, a histological scoring was made from 20 random 
fields per section from each specimen (Table 3). After 
histological confirmation of induction of UC in all 
animals, they were randomly divided into two groups. 
Group A received C. officinalis extract via enema 
(40% solution, 3 mL/day until 30 days) and Group B 
that received a saline enema (3 mL/day). 
Table 1: Criteria for scoring of macroscopic damage
a.
Score       Macroscopic morphology    
0               No damage 
1               Localized hyperemia, but no ulcer 
2               Linear ulcers with no significant inflammation 
3               Linear ulcer with inflammation at one site 
4               Two or more sites of ulceration and/or inflammation 
5               Two or more major sites of inflammation and ulceration or one major site     
                  inflammation and ulceration extending 41 cm along the length of the colon 
a An Inflammation was defined as regions of hyperemia and bowel wall thickening. Mehrabani et al. 
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An identical rigid rectosigmoidoscopy was repeat-
ed after 14 and 30 days of UC induction to provide 
multiple biopsies from the mucosa for histological 
study. After 45 days, another rigid rectosigmoidosco-
py was performed to take biopsies for histological 
evaluation. According to the criteria described by 
Dundar et al. (2008) for severity of colitis, all dogs 
were scored.
19 For histological study, the animals 
were sacrificed with an overdose of anesthetics. All 
statistical analyses were performed with the Statistical 
Package for Social Sciences version 16.0 (SPSS Inc., 
Chicago, Ill., USA). Chi-square test was used to com-
pare the proportions between groups. A p value of less 
than 0.05 was considered statistically significant. 
 
 
Results  
 
In dogs received 6 ml/kg of 6% acetic acid for two 
days, typical changes related to ulcerative colitis e.g. 
Table 2: The variables used for microscopic scoring.
Variable  Severity of changes
0 1 2 3 
Ulceration  No ulcer  Erosion or single 
ulceration not ex-
ceeding lamina 
muscularis muco-
sa
Multifocal ulcera-
tions not exceeding 
the submucosa 
Ulcerations exceed-
ing the submucosa 
Mucus cell deple-
tion 
Preserved mu-
cus cell 
Mild depletion in a 
few cells 
Moderate depletion 
(<50% of cells) 
Severe depletion or 
complete disappear-
ance of mucosa
Crypt abscesses  No abcesses  1–3 abscesses/ 
slide 
4–9 abscesses/slide  10 or more abscess-
es/slide 
Inflammatory cysts  No cysts  1–3 cysts/slide  4–9 cysts/slide  10 or more 
cysts/slide 
Mucosal atrophy  Normal thick-
ness 
Mild atrophy 
(<10%)
Moderate atrophy 
(10–50%)
Severe atrophy 
(<50%) 
Edema 
(submucosa) 
Normal thick-
ness 
Mild edema (sub-
mucosal Expan-
siono<10%)
Moderate edema 
(submucosal expan-
sion, 10–100%)
Severe edema (sub-
mucosal Expan-
sion>100%) 
Inflammatory cell 
infiltration 
No inflammato-
ry cell infiltra-
tion 
Mild inflammatory 
cell infiltration 
Moderate (distribut-
ed but not dense) 
inflammatory cell 
Dense inflammatory 
cell infiltration 
Vascular dilatation  Normal blood 
vessels 
Mild dilatation of 
single blood ves-
sel 
Moderate dilatation 
of several blood 
vessels 
Severe dilatation of 
several blood vessels 
 
 
Table 3: Results of  treatment in group A.
Variable After  7  days
(Before treatment) 
After 14 days After 30 days         After 45 days
 (p=0.04)                  (p=0.005) 
  1   2   3   4   5 1 2 3 4 5 1 2 3 4 5     1  2  3  4  5
Ulceration  0   1   1   0   0  0  0  1 0  0  0  0  0 0  0     0  0  0  0  0 
Mucous cell depletion  0   1   1   2   2 0 1 0 1 1 0 1 0 0 0     0  0  0  0  0
Crypt abscess  1   1   1   1   1  0  1  1 1  1  0  0  0 0  1     0  0  0  0  0 
Inflammatory cyst  0   0   0   0   0  0  0  0 0  0  0  0  0 0  0     0  0  0  0  0 
Mucosal atrophy  1   1   1   1   1 0 0 1 1 1 0 0 0 0 0     0  0  0  0  0
Submucosal edema  1   1   1   1   1  0  0  1 1  1  0  0  0 0  1     0  0  0  0  0 
Inflammatory cell  2   2   3   2   2  1  1  2 2  2  1  1  1 1  1     0  0  0  0  0 
Vascular dilatation  2   2   2   2   2 1 2 2 2 2 1 2 2 2 1     0  0  0  0  0
   Total  7   9  10  9   9  3  5  7 8  8  2  4  3 3  4     0  0  0  0  0 
 C. officinalis in ulcerative colitis 
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multiple ulcers and diffuse inflammation were noticed 
with a score of 5. After 7 days, the biopsies revealed 
inflammatory cells in mucosa and around the crypts that 
were polymorphonuclear leukocytes and lymphocytes. 
Multiple ulcerations were also noticed indicating to 
presence of a crypt abscess. In the submucosa, multifo-
cal areas of inflammation and ulceration were present 
and it was diffusely edematous. Infiltration of polymor-
phonuclear leukocytes, eosinophils and lymphocytes 
was extensive. Figure 1 demonstrates a severe inflam-
mation, PMN infiltration in lamina propria, glandular 
destruction and goblet cell depletion denoting to UC 
after 7 days (x400, H&E); Figure 2 shows a mild PMN 
infiltration and goblet cell depletion after 30 days (x100, 
H&E) and Figure 3 denotes to a complete healing after 
45 days (x400, H&E).  
 
 
Fig. 1: Severe inflammation, PMN infiltration in lami-
na propria, glandular destruction and goblet cell de-
pletion denoting to UC after 7 days (x400, H&E). 
 
 
Fig. 2: Mild PMN infiltration and goblet cell depletion 
after 30 days (x100, H&E). 
 
Fig. 3: Complete healing after 45 days of treatment 
(x400, H&E). 
 
Table 3 shows the findings of retrograde treatment 
by C. officinalis in dogs. On day 7
th, the scoring was 
7-10, on day 14
th was 3-8, on day 30
th was 2-4 and 0 
on 45
th day. 
On days 14
th ( p>0.05), 30
th ( p=0.04) and 45
th 
(p=0.005), the mucosal healing was statistically sig-
nificant compared to the 7
th and 14
th day.  
 
 
Discussion  
 
Many reports showed that hamsters, mice or rats as 
experimental models of UC.
20-23 Administration of 
6% acetic acid into the colon led to a fast develop-
ment of severe inflammation and ulceration of the 
colon together with diarrhea, hematochezia and 
weight loss that are identical to what occurs in human 
UC. In this study, macroscopic findings were ulcera-
tion and hemorrhage. Microscopic findings were an 
increase in infiltration of polymorphonuclear leuko-
cytes, lymphocyte and presence of cryptic abscesses 
similar to human UC. 
Regarding UC induction, there are several reports 
on different chemicals to induce experimental colitis 
such as acetic acid, 2,4,6-trinitrobenzene sulfonic acid, 
dextran sodium sulfate, oxazolone and indomethacin.
24 
In this study, 6% acetic acid was used for induction of 
UC. It is easily available and an inexpensive chemical 
agent. Our findings confirmed induction of UC 
sigmoidoscopically and histologically.  
Many methods of treatment of UC are used in 
experimental animal models such as corticosteroids, 
salazosulfapyridine, azathioprine, mesalazine, 
methotrexate, 6-mercaptopurine, and cyclosporin.
25 Mehrabani et al. 
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They are mostly targeted to reduce symptoms of UC. 
However clinically, the therapeutic measure that can 
prevent a relapse may also be as important as a 
treatment to decrease symptoms.
26 They demonstrated 
that fibratide decreased the severity of experimental 
dextran sulfate sodium (DSS)-induced UC in mice 
and reported that it can be potentially beneficial in 
treatment of inflammatory bowel diseases (IBD). 
Topical use of GM-CSF on mucositis reduced the 
duration of healing time via suppressing 
inflammatory reaction and proliferating epithelia.
20 
Tozaki et al. showed that chitosan capsules were useful 
carriers in colon-specific delivery of anti-inflammatory 
drugs such as 5-ASA and the healing of TNBS-
induced colitis in rats.
27 Treatment with ECP antibody 
was shown to improve DSS-induced colitis in rats, 
probably because of increased regenerative activity of 
the colonic epithelium and downregulation of the 
immune response. Therefore, anti-ECP may promote 
intestinal wound healing in patients with UC.
23  
The colonic mucosal layer was shown as a potential 
therapeutic target for IBD based on the histological 
findings that in IBD patients, a thinner mucosal layer 
and depletion of goblet cells in the colonic epithelium 
are seen.
28 The mucosal layer is mostly composed of 
mucins and acts as a physical barrier to protect the 
epithelium from agents disturbing epithelium integrity 
and may also prevent the intestinal microflora from 
triggering abnormal immune responses.
28 They 
Showed that in mice with disrupted mucus synthesis 
suffered from more serious colitis, presence of mucus 
is important in inflammation.
28 An injury in the 
gastrointestinal tissue is usually associated with 
healing needing the production of granulation tissue 
including deposition of connective tissue matrix, 
proliferations of fibroblasts and angiogenesis for 
reconstruction of mucosal microvessels that are critical 
for delivery of oxygen and nutrients to the healing 
site.
28 In last step of healing, re-epithelialization and 
reconstruction of epithelial structures occurs.
29  
After development of injury in the mucosal layer, 
the intestinal epithelium would reestablish fast its 
integrity. To reestablish the integrity of the mucosal 
layer, epithelial cells migrate into the wounded area 
(epithelial restitution) and would later proliferate to 
replace the decrease in the cell pool. A variety of 
soluble peptides, growth factors, prostaglandins and 
cytokines are also secreted in a coordinated fashion in 
the injured area to restore mucosal integrity.
30  
Calendula officinalis is a herb having medicinal 
properties containing biologically active complex 
substances of Carotin (Provitamin A), Stearin, Triter-
piniod, Plavonoid, Kumarin, macro and micro com-
pound elements.
31 There are several reports on differ-
ent properties of Calendula officinalis L. showing that 
this herbal is effective in protection against subacute 
ciggaret smoking-induced cell injury,
32 has antimeta-
static effects,
33 antiparasitic and antibacterial effica-
cies,
34,35 spasmolytic properties,
36 wound healing and 
anti-inflammatory properties,
37,38 hepato- and reno- 
protective action,
39 and Angiogenic activity.
14 There 
are no data available on anti ulcer effect of this herbal 
in IBDs. Our findings denote to a significant mucosal 
healing after administration of C. officinalis after 30 
and 45 days.  
We showed that our therapy could well resolve the 
damages. So C. officinalis may provide an 
opportunity for UC therapy and broaden the current 
treatment choices.  
 
 
Acknowledgement 
 
The authors would like to thank Shiraz University of 
Medical Sciences for financial support and the Labor-
atory Animal Center for their cooperation. 
 
Conflict of interest: None declared. 
 
 
References 
 
 
 
 
1  Ho GT, Chiam P, Drummond H, 
Loane J, Arnott ID, Satsangi J. The 
efficacy of corticosteroid therapy in 
inflammatory bowel disease: 
Analysis of a 5 year UK inception 
cohorot.  Aliment Pharmacol Ther 
2006;2:319-30. [16842459]  [http:// 
dx.doi.org/10.1111/j.1365-2036.200 
6.02974.x]  
2  Cetinkaya A, Bulbuloglu E, Kurutas 
EB, Ciralik H, Kantarceken B, Buyuk-
bese MA. Beneficial effects of N-
acetylcysteine on acetic acid-induced 
colitis in rats. Tohoku J Exp Med 
2005;206:131-9. [15888969] [http:// 
dx.doi.org/10.1620/tjem.206.131] 
3  Burger D, Travis S. Conventional 
medical management of inflammatory 
bowel disease. Gastroenterology 
2011;140:1827-1837.e2. [215 30749] 
[http://dx.doi.org/10.1053/j.gastro.20 
11.02.045] 
4  Triantafillidis JK, Merikas E, Georgop-
oulos F. Current and emerging drugs 
for the treatment of inflammatory bow-
el disease. Drug Des Devel Ther 
2011;5:185-210. [21552489] 
[http://dx.doi.org/10.2147/DDDT.S11
290] 
5  Bossa F, Colombo E, Andriulli A, 
Annese V. Treatment of steroid-
naive ulcerative colitis. Expert Opin 
Pharmacother 2009;10:1449-60. [19 C. officinalis in ulcerative colitis 
 
WWW.ircmj.com Vol 13 December 2011  889
445560] [http://dx.doi.org/10.1517/ 
14656560902973728] 
6  Faure M, Moënnoz D, Montigon F, 
Mettraux C, Mercier S, Schiffrin EJ, 
Obled C, Breuillé D, Boza J. Mucin 
production and composition is altered 
in dextran sulfate sodium-induced co-
litis in rats. Dig Dis Sci 2003; 
48:1366-73. [12870797] [http://dx. 
doi.org/10.1023/A:1024175629909] 
7  Basch E, Bent S, Foppa I, Haskmi 
S, Kroll D, Mele M, Szapary P, Ul-
bricht C, Vora M, Yong S; Natural 
Standard Research Collaboration. 
Marigold (Calendula officinalis L.): 
an evidence-based systematic review 
by the Natural Standard Research 
Collaboration.  J Herb Pharmacother 
2006;6:135-59. [17317655] [http://dx. 
doi.org/10.1080/J157 v06n03_08] 
8  Yoshikawa M, Murakami T, Kishi A, 
Kageura T, Matsuda H. Medicinal 
flowers. III. Marigold. (1): hypoglyce-
mic, gastric emptying inhibitory, and 
gastroprotective principles and new 
oleanane-type triterpene oligoglyco-
sides, calendasaponins A, B, C, and 
D, from Egyptian Calendula offici-
nalis.  Chem Pharm Bull (Tokyo) 
2001;49:863-70. [11456093] [http:// 
dx.doi.org/10.1248/cpb.49.863] 
9  Ukiya M, Akihisa T, Yasukawa K, 
Tokuda H, Suzuki T, Kimura Y. Anti-
inflammatory, anti-tumor-promoting, 
and cytotoxic activities of constituents 
of marigold (Calendula officinalis) 
flowers. J Nat Prod 2006;69: 1692-6. 
[17190444] [http://dx.doi.org/10.102 
1/np068016b] 
10  Preethi CK, Kuttan G, Kuttan R. Anti 
inflammatory activity of flower ex-
tract of Calendula officinalis Linn. 
And its possible mechanism of ac-
tion. Indian J Exp Biol 2009;47:113-
20. [19374166] 
11  Andersen FA, Bergfeld WF, Belsito 
DV, Hill RA, Klaassen CD, Liebler 
DC, Marks JG Jr, Shank RC, Slaga 
TJ, Snyder PW. Final report of the 
Cosmetic Ingredient Review Expert 
Panel amended safety assessment 
of Calendula officinalis-derived 
cosmetic ingredients. Int J Toxicol 
2010;29:221S-43. [21164072] [http:// 
dx.doi.org/10.1177/1091581810384
883] 
12  Fonseca YM, Catini CD, Vicentini 
FT, Cardoso JC, Cavalcanti De Al-
buquerque Junior RL, Vieira Fonse-
ca MJ. Efficacy of marigold extract-
loaded formulations against UV-
induced oxidative stress. J Pharm 
Sci 2011;100:2182-93. [21 491442] 
[http://dx.doi.org/10.1002/ 
jps.22438] 
13  Preethi KC, Siveen KS, Kuttan R, 
Kuttan G. Inhibition of metastasis of 
B16F-10 melanoma cells in 
C57BL/6 mice by an extract of Ca-
lendula officinalis L flowers. Asian 
Pac J Cancer Prev 2010;11:1773-9. 
[21338232] 
14  Parente LM, Andrade MA, Brito LA, 
Moura VM, Miguel MP, Lino-Júnior 
Rde S, Tresvenzol LF, Paula JR, 
Paulo NM. Angiogenic activity of 
Calendula officinalis flowers L. in 
rats.  Acta Cir Bras 2011;26:19-24. 
[21271199] 
15  Medhi B, Prakash A, Avti PK, Saikia 
UN, Pandhi P, Khanduja KL. Effect 
of Manuka honey and sulfasalazine 
in combination to promote antioxi-
dant defense system in experimen-
tally induced ulcerative colitis model 
in rats. Indian J Exp  Biol 2008; 
46:583-90. [18814487] 
16  Souza MM, Aguilar-Nascimento JE, 
Gomes-da-Silva MH, Carlos Junior 
R. Effects of budesonide and probi-
otics enemas on the colonic mucosa 
of rats with experimental colitis. Acta 
Cir Bras 2007;22:34-8. [17293947] 
[http://dx.doi.org/10.1590/S0102-86 
502007000100006] 
17  Morris DL, Montgomery SM. Galloway 
ML, Pounder RE, Wakefield AJ. 
Inflammatory bowel disease and 
laterality: is left handedness a risk? 
Gut  2001;49:199-202. [11454794] 
[http://dx.doi.org/10.1136/gut.49.2.1
99] 
18  Mehrabani D, Rezaee A, Azarpira 
N, Fattahi MR, Amini M, Tanideh N, 
Panjehshahin MR, Saberi-Firouzi M. 
The healing effects of Teucrium 
polium in the repair of indomethacin-
induced gastric ulcer in rats. Saudi 
Med J 2009;30:494-9. [19370274] 
19  Dundar E, Olgun EG, Isiksoy S, 
Kurkcuoglu M, Baser KH, Bal C. 
The effects of intra-rectal and intra-
peritoneal application of Origanum 
onites L. essential oil on 2,4,6-
trinitrobenzenesulfonic acid-induced 
colitis in the rat. Exp Toxicol Pathol 
2008;59:399-408. [18222658] [http:// 
dx.doi.org/10.1016/j.etp.2007.11.009] 
20  Cho SA, Park JH, Seok SH, Juhn JH, 
Kim SJ, Ji HJ, Choo YS, Park JH. 
Effect of granulocyte macrophage-
colony stimulating factor (GM-CSF) 
on 5-FU-induced ulcerative mucositis 
in hamster buccal pouches. Exp 
Toxicol Pathol 2006;57:321-8. [1641 
4253] [http://dx.doi.org/10.1016/j. 
etp.2005.09.006] 
21  Faure M, Moënnoz D, Montigon F, 
Mettraux C, Mercier S, Schiffrin EJ, 
Obled C, Breuillé D, Boza J. Mucin 
production and composition is al-
tered in dextran sulfate sodium-
induced colitis in rats. Dig Dis Sci 
2003;48:1366-73. [12870797] [http:// 
dx.doi.org/10.1023/A:1024175629909] 
22  Reber SO, Obermeier F, Straub RH, 
Falk W, Neumann ID. Chronic 
intermittent psychosocial stress 
(Social Defeat/Overcrowding) in 
mice increases the severity of an 
acute DSS-induced colitis and 
impairs regeneration. Endocrinology 
2006;147:4968-76. [16794011] [http:// 
dx.doi.org/10.1210/en.2006-0347]  
23  Shichijo K, Makiyama K, Wen CY, 
Matsuu M, Nakayama T, Nakashima 
M, Ihara M, Sekine I. Antibody to 
eosinophil cationic protein suppresses 
dextran sulfate sodium-induced colitis 
in rats. World J Gastroenterol 
2005;11:4505-10. [16052679]  
24  Kawada M, Arihiro A, Mizoguchi E. 
Insights from advances in research of 
chemically induced experimental 
models of human infl ammatory 
bowel disease. World J Gastroenterol 
2007;13:5581-93. [17948932]  
25  Hanauer SB, Present DH. The state 
of the art in the management of 
inflammatory bowel disease. Rev. 
Gastroenterol Disord 2003;3:81-92. 
[12776005] 
26  Lin X, Zamora PO, Takahashi K, Lui 
Y. Alleviation of experimental 
ulcerative colitis with the synthetic 
peptide, F2A4-K-NS (Fibratide). Dig 
Dis Sci 2007;52:2054-62. [174048 
50] [http://dx.doi.org/10.1007/s10 
620-006-9641-z]  
27  Tozaki H, Odoriba T, Okada N, 
Fujita T, Terabe A, Suzuki T, Okabe 
S, Muranishi S, Yamamoto A. C 
hitosan capsules for colon-specific 
drug delivery: enhanced localization 
of 5-aminosalicylic acid in the large 
intestine accelerates healing of 
TNBS-induced colitis in rats. J 
Controlled Release 2002;82:51-61. 
[12106976] [http://dx.doi.org/10.10 
16/S0168-3659(02)00084-6] 
28  Van der Sluis M, De Koning BA, De 
Bruijn AC, Velcich A, Meijerink JP, 
Van Goudoever JB, Büller HA, 
Dekker J, Van Seuningen I, Renes 
IB, Einerhand AW. MUC2-deficient 
mice spontaneously develop colitis, 
indicating that MUC2 is critical for 
colonic protection. Gastroenterology 
2006;131:117-29. [16831596] [http:// 
dx.doi.org/10.1053/j.gastro.2006.04.
020] 
29  Tarnawski A. Cellular and molecular 
mechanisms of gastrointestinal ulcer 
healing.  Dig Dis Sci 2005;50:S24-
33. [16184417] [http://dx.doi.org/ 
10.1007/s10620-005-2803-6] 
30  Brun P, Mastrotto C, Beggiao E, 
Stefani A, Barzon L, Sturniolo GC, 
Palù G, Castagliuolo I. Neuropeptide 
neurotensin stimulates intestinal 
wound healing following chronic 
intestinal inflammation. Am J 
Physiol Gastrointest Liver Physiol 
2005;288:G621-9. [15764810] [http:// 
dx.doi.org/10.1152/ajpgi.00140.2004] 
31  Korakhashvili A, Kacharava T, 
Kiknavelidze N. Biochemical struc-
ture of Calendula officinalis. Geor-
gian Med News 2007;148-149:70-3. 
[179 21550] Mehrabani et al. 
 
WWW.ircmj.com Vol 13 December 2011  890
32  Ozkol H, Tülüce Y, Koyuncu I. Sub-
acute effect of cigarette smoke ex-
posure in rats: Protection by pot 
marigold (Calendula officinalis L.) 
extract.  Toxicol Ind Health 2011; 
[21505008] 
33  Preethi KC, Siveen KS, Kuttan R, 
Kuttan G. Inhibition of metastasis of 
B16F-10 melanoma cells in 
C57BL/6 mice by an extract of Ca-
lendula officinalis L flowers. Asian 
Pac J Cancer Prev 2010;11:1773-9. 
[21338232] 
34  Szakiel A, Ruszkowski D, Grudniak 
A, Kurek A, Wolska KI, Doligalska 
M, Janiszowska W. Antibacterial 
and antiparasitic activity of oleanolic 
acid and its glycosides isolated from 
marigold (Calendula officinalis). 
Planta Med 2008;74:1709-15. [189 
51335] [http://dx.doi.org/10.1055/s-
0028-1088315] 
35  Lans C, Turner N, Khan T.Medicinal 
plant treatments for fleas and ear 
problems of cats and dogs in British 
Columbia, Canada. Parasitol Res 
2008;103:889-98. [18563443] [http: 
//dx.doi.org/10.1007/s00436-008-10 
73-6] 
36  Bashir S, Janbaz KH, Jabeen Q, 
Gilani AH. Studies on spasmogenic 
and spasmolytic activities of Calen-
dula officinalis flowers. Phytother 
Res  2006;20:906-10. [16906636] 
[http://dx.doi.org/10.1002/ptr.1980] 
37  Fronza M, Heinzmann B, Hamburg-
er M, Laufer S, Merfort I. Determina-
tion of the wound healing effect of 
Calendula extracts using the scratch 
assay with 3T3 fibroblasts. J Basic 
Clin Physiol Pharmacol 2009; 20:73-
9. [19601397] 
38  Preethi KC, Kuttan R. Wound heal-
ing activity of flower extract of Ca-
lendula officinalis. Indian J Exp Biol 
2009;47:163-8. [19405380] 
39  Preethi KC, Kuttan G, Kuttan R. 
Hepato and reno protective action of 
Calendula officinalis L. flower ex-
tract. Indian J Exp Biol 2009;47:113-
20. [19374166] 
 